Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Esophageal Cancer: early-phase trial registry
63 of 132 indexed Esophageal Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #88 of 28,707 conditions by registered trial count.
132 US clinical trials · 63 currently recruiting · #88 of 28,707 conditions by registered trial count
Esophageal Cancer: 132 US clinical trials tracked, 63 recruiting.
Esophageal Cancer is the subject of 132 registered US clinical trials on ClinicalTrials.gov, 63 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 84 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 10 of these trials.
Enrollment posture brief
Registry condition esophageal-cancer
OPEN 63 | RECR 48% | LATE 8 | EARLY 84 | RANK #88 | SPON 10
Volume-matched condition peers
Nearest open-share peer: Alcohol Drinking (48% recruiting · 86 trials)
Esophageal Cancer lists 63 open slots (48% of 132 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Esophageal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Esophageal Cancer is recruiting above its size-band peers.
63 of 132 indexed trials (47.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Esophageal Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 10 of 132 trials (7.6%). 89 distinct sponsors appear on at least one study for this condition label.
-
Typical Esophageal Cancer enrolment sits around 80 participants.
Median target enrolment is 80 among the 124 trials that report a genuine target (sentinel values excluded). 69 of those (55.6%) plan for fewer than 100 participants.
-
Esophageal Cancer research is mostly interventional.
106 interventional and 26 observational studies make up this index (80.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
132 total, page 2 of 3
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Baylor College of Medicine
NCT03740256
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
NCT05187182
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Zumutor Biologics
NCT06451497
Volume Outcome Relationships and Effects
Methodist Health System
NCT06343597
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America
NCT06943521
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
Lantheus Medical Imaging
NCT06298916
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
University of Michigan Rogel Cancer Center
NCT05183126
Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)
University of Pittsburgh
NCT06872515
Exercise Prehabilitation for Locoregional Esophageal Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT06430346
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
NCT07001592
Hypoxia Imaging for Esophageal Cancer to Guide Personalized Radiation Therapy
University of Utah
NCT04846309
Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)
Cedars-Sinai Medical Center
NCT07124351
Brodalumab in the Treatment of Immune-Related Adverse Events
Brian Henick, MD
NCT06673329
Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract
Memorial Sloan Kettering Cancer Center
NCT00582647
Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial
M.D. Anderson Cancer Center
NCT01512589
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals
NCT05215574
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Uswm CT
NCT04044859
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Qurient Co.
NCT05438420
BEST-RPP Pilot: Screening for Esophageal Cancer in Rural Oregon Without an Endoscopy
OHSU Knight Cancer Institute
NCT06335966
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics
NCT05864144
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
NextCure
NCT05572684
Sentinel Lymph Node Mapping in Esophageal Cancer Using ICG Dye and NIR Imaging
Memorial Sloan Kettering Cancer Center
NCT04400292
Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers
Duke University
NCT03403465
MAGE-A4ᶜ¹º³²T for Multi-Tumor
Adaptimmune
NCT03132922
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals
NCT05311618
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Immunitas Therapeutics
NCT05565417
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
Legend Biotech USA
NCT05539430
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Arcus Biosciences
NCT05891171
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
NCT03174275
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03044613
Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer
Abramson Cancer Center at Penn Medicine
NCT02213497
Proton Beam Therapy in the Treatment of Esophageal Cancer
Washington University School of Medicine
NCT03482791
Cryotherapy for Locally Advanced Esophageal Cancer
Hunter Holmes Mcguire Veteran Affairs Medical Center
NCT04248582
Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
Washington University School of Medicine
NCT04046575
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
Brown University
NCT05480384
Genetic and Environmental Risk Factors Related to Esophageal Cancer
Massachusetts General Hospital
NCT01035398
PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine
Labcorp Corporation of America Holdings
NCT05697198
Evaluations of Alcohol Warning Labels
University of Connecticut
NCT06129487
Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer
Alliance for Clinical Trials in Oncology
NCT00052910
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Alliance for Clinical Trials in Oncology
NCT02349412
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Alliance for Clinical Trials in Oncology
NCT01333033
Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin
Dana-Farber Cancer Institute
NCT00831571
Interactive Voice Response System (IVRS) for Managing Symptoms of Patients Following Thoracic Surgery
M.D. Anderson Cancer Center
NCT00505024
Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis
Covenant Health Cancer Center
NCT05369234
S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction
SWOG Cancer Research Network
NCT00086996
Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
Eastern Cooperative Oncology Group
NCT00033657
Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer
Case Comprehensive Cancer Center
NCT00258323
PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery
Memorial Sloan Kettering Cancer Center
NCT00002930
S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus
SWOG Cancer Research Network
NCT00012363
Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer
Dana-Farber Cancer Institute
NCT00165464
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 49 |
| Phase 2 | 35 |
| Phase 3 | 5 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Esophageal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Esophageal Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Esophageal Cancer page
132 registered trials, 63 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 63 Esophageal Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Esophageal Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Esophageal Cancer condition card totals 132 registered trials; most-linked intervention radiation therapy; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.